FDMT

4D Molecular Therapeutics, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-18

Figures on this page computed 2026-11-07 11:37 UTC

Last close

12.28USD

Market data, 2026-11-04

FDMT: weekly closes from 10.50 on 2025-11-07 to 12.28 on 2026-11-04, a move of +17.0%. Prices in USD.

Weekly closes, 2025-11-07 to 2026-11-04

Over that span: +17.0%

Except where said otherwise: 10-K for 2025, filed 2026-03-18

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
-164.4%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
-128.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
0.04Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.12 against 0.23 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

4.57x

1.78x

1.63x

1.15x

0.74x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-18

Sales4.57x
Its own average over 9 years, 18.6M.
Profit1.78x
Its own average over 9 years, -78.6M.
Free cash flow1.63x
Its own average over 9 years, -67.1M.
Debt1.15x
Its own average over 5 years, 18.7M.
Price0.74x
Its own average over 7 years, 17. Market data, 2026-11-04

Sales is furthest from its own average, at 4.57 times.

The filed years, as a table

Each line is 100 at 2017-12-31, the first year we hold.

Filed year	Sales	Shares in issue
2017-12-31	100.0	100.0
2018-12-31	244.0	84.4
2019-12-31	120.7	n/a
2020-12-31	235.1	n/a
2021-12-31	311.5	186.9
2022-12-31	54.0	218.1
2023-12-31	357.9	263.8
2024-12-31	0.6	363.6
2025-12-31	1,471.7	390.5

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-114075
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001193125-26-114075
Reported in: USD

The filing itself

Figures behind the shape

Growth

44.3%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate44.3%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
One-year change in net income12.9%
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Returns on capital

-27.7%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on equity-27.7%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Return on assets-24.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself

Margins

-187.2%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross marginn/a
We do not hold this figure for this company, so there is nothing to place.
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Operating margin-187.2%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Net margin-164.4%
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Free cash flow margin-128.7%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself

Price

1.4x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earningsn/a
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
Price to book1.4x10-Q for 2025, filed 2026-08-13
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-349173
Reported in
USD
- computed
- 10-Q for 2025, filed 2026-08-13
- computed
- 10-K for 2025, filed 2026-03-18
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
- 10-K for 2025, filed 2026-03-18
The filing itself
Price to sales ratio8.3x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself

Safety

0.04

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equity0.04
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-Q for 2025, filed 2026-08-13
The filing itself
Current ratio9.3910-Q for 2025, filed 2026-08-13
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001193125-26-349173
Reported in
USD
- 10-Q for 2025, filed 2026-08-13
- 10-Q for 2025, filed 2026-08-13
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Altman Z-Score5.21
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-06
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001193125-26-114075
Reported in
USD
- 10-K for 2025, filed 2026-03-18
- Computed from the 10-K for 2025, filed 2026-03-18
- 10-K for 2025, filed 2026-03-18
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-06
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.